Norges Bank’s Akero Therapeutics AKRO Stock Holding History

Norges Bank’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-136,377	Closed	-$6.37M	–	1967
2023 Q2	$6.37M	Sell	136,377 -134,199	-50%	-$6.15M	﹤0.01%	1658
2023 Q1	$10.4M	Buy	270,576 +95,676	+55%	+$4.27M	﹤0.01%	1566
2022 Q4	$9.58M	Buy	+174,900	New	+$7.49M	﹤0.01%	1588
2019 Q3	–	Sell	-15,000	Closed	-$287K	–	2090
2019 Q2	$287K	Buy	+15,000	New	+$284K	﹤0.01%	2074

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Norges Bank's AKRO Position: Q3 2023 in Review

Norges Bank sold out of Akero Therapeutics (AKRO) in Q3 2023, closing a stake of 136,377 shares — an estimated $6.37M sold.

Norges Bank first reported a position in AKRO in Q2 2019 and held it in 4 quarters. The position peaked at $10.4M in Q1 2023. 181 funds tracked by Wall St. Rank hold AKRO as of Q3 2023.

Norges Bank reported no remaining Akero Therapeutics position as of Q3 2023 after selling out during the quarter.
Norges Bank sold 136,377 Akero Therapeutics shares in Q3 2023, an estimated $6.37M.
Norges Bank first reported a position in Akero Therapeutics in Q2 2019 and held it in 4 quarters.
Norges Bank's Akero Therapeutics position peaked at $10.4M in Q1 2023.
181 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2023.

Based on Norges Bank's 13F filing for Q3 2023, filed 13 Nov 2023.